Skip to main content
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. — Investor Relations & Filings

Listed
Ticker · FULC ISIN · US3596161097 US Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2026-06-11 Board/Management Inform…
Country US United States of America
Listing US FULC · 3 venues

About Fulcrum Therapeutics, Inc.

https://www.fulcrumtx.com/

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule therapies for genetically defined diseases with high unmet medical needs. The company utilizes a proprietary technology platform to identify drug targets that can modulate gene expression, aiming to treat the root cause of a disease. This approach focuses on regulating genes that are incorrectly expressed. Fulcrum's pipeline is concentrated on creating disease-modifying treatments for rare conditions, with key programs in sickle cell disease and facioscapulohumeral muscular dystrophy (FSHD).

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 96% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically Item 5.02, which details departures and appointments of officers and amendments to employment agreements for existing executives. It announces changes in senior management compensation and personnel departures. Therefore, it matches the Board/Management Information category.
2026-06-11 English
8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K “Current Report” filed with the SEC, disclosing Items 2.05 (Costs Associated with Exit or Disposal Activities) and 8.01 (Other Events regarding a strategic review). It is not a full financial report (10-K or interim), earnings release, proxy, or M&A filing, but rather a required current report under the Exchange Act. This falls under the general Regulatory Filings category (RNS).
2026-06-04 English
8-K
Regulatory Filings Classification · 92% confidence The document is an SEC Form 8-K current report describing "Other Events" (the discontinuation of a program and strategic review) and attaching a press release. It is a regulatory announcement filing under the Securities Exchange Act rather than a substantive financial report, earnings release, or management discussion. It does not fit any specialized category (e.g., earnings release, M&A, board changes) and is thus a general regulatory filing. Therefore, it should be classified under Regulatory Filings (RNS).
2026-06-01 English
10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-27 English
8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes termination of a material definitive agreement, announcement of quarterly financial results via a press release, appointment of a new director, and retirement of the CFO. The document references the press release for quarterly financial results but does not itself contain detailed financial statements or substantive financial data. The document is not an Annual Report (10-K), Interim Report (10-Q or IR), or Earnings Release (ER) by itself. It is a regulatory filing reporting multiple corporate events and referencing other filings. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-27 English
SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
Major Shareholding Notification
2026-03-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.